This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients with residual cardiovascular disease (CVD) risk, using triglyceride-rich lipoprotein (TGRL) science and management. The program is based on a live satellite symposium (held during the time of AHA-2018), where REDUCE-IT results were 1st presented after a late-breaking clinical trial presentation. Challenges faced by healthcare providers in caring for patients with elevated TGRL are addressed. Topics include:
- Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy
- Biologic Basis for TGRL Modulation in Reducing Atherosclerosis
- Clinical Evidence on Reducing TGRL-based Residual Risk: REDUCE-IT
For more information, contact Medtelligence, LLC at firstname.lastname@example.org.